echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Lancet oncol: The quality of life of metastatic despotic prostate cancer patients treated with kabatha.

    Lancet oncol: The quality of life of metastatic despotic prostate cancer patients treated with kabatha.

    • Last Update: 2020-10-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    In the CARD study, cabazitaxel (kabatasai) significantly extended the progression-free survival of patients with metastatic degenerative resistance prostate cancer treated with too much cyclocycline and androgen targeted inhibitors.
    is now a summary of the quality of life prognossing of card studies.
    CARD was a randomized, open-label Phase 4 study conducted at 62 clinical centres in 13 European countries, in which patients diagnosed with metastatic desopathic prostate cancer over the age of 18 were randomly assigned to the Kabatha group (25 mg/m2, static drops) at 1:1. , once every 3 weeks; strong pine, 10 mg/day and granulocyte set stimulation factor) vs Abitron group (1000 mg/day plus strong pine 5 mg.2/day) or Enrugrumam group (160 mg/day, oral).
    end point is progress-free survival.
    November 17, 2015 - November 28, 2018, a total of 303 patients were screened, 255 of whom were randomly assigned to the Kabata group (n-129) or the abitron/ensergide group (n-126).
    followed for 9.2 months (range 5.6-13.1 months).
    51 (46%) of the 111 patients in the Kabata group and 21 (19%) of the 109 patients in the abitron/enrugluamine group received pain relief.
    the progression of pain symptoms in the kabata group and the mid-term time for bone-injury symptoms were not reached, and the abitron/ensergide group was 8.5 months (4.9-failed; risk ratio was 0.55, 95% CI 0.3) 2-0.97; p-0.050) and 16.7 months (10.8-failed; 0.59,95% CI 0.35-1.01, p-0.050).
    the total FACT-P score of the Kabata group deteriorated by 14.8 months, while the Abitron/Enserooamine group had a medium time of 8.9 months (HR 0.72, 95% CI 0.44-1.20, p=0.21). The baseline value change of the EQ-5D-5L utility index score of the
    Kabata group was also significantly better than that of the Abitron/Enruguruamine group, but there was no difference in the baseline change of the EQ-5D-5L visual simulation scale between the treatment groups.
    study showed that kabathal improved pain relief, delayed pain progression, and the time of skeletal symptoms, as well as the EQ-5D-5L utility index score, which does not degrade quality of life compared to the use of second-generation androgen signal target inhibitors.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.